A Phase 4 interventional study of Marcaine and Saline in Chronic Migraine, sponsored by Tian Medical Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-01-26.
Sponsored by Tian Medical Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing bupivacaine in Migraine Disorders — 4 open to participants now, 4 under way, 1 of them phase 3. Bupivacaine · Migraine Disorders.
Among the 14 studies testing bupivacaine in Migraine Disorders, this one is the 10th largest by enrollment, is one of 2 that started in 2012, is one of 5 in phase 4, and was the 2nd registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →4 of the 14 studies testing bupivacaine in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18–80
HCA Florida North Florida Hospital · Sites in United States
Ages 18+
Mahidol University · Sites in Thailand
Ages 18–65
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 2 · Phase 4 5
First in 2009; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 55 across the 14 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
Tian Medical Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Tian Medical Inc. has 2 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies testing bupivacaine in Migraine Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05734625Mayo ClinicEfficacy of Nerve Blocks for Episodic Migraine | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing bupivacaine in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Migraine imposes a substantial burden on patients in terms of diminished daily functioning, quality of life, and financial loss. Pain severity and duration correlates with reduced measures of daily functioning, and overall health status. The sphenopalatine ganglion (SPG) has been implicated in a variety of cephalalgias. This has been well represented in the literature dating back over a century. Access to this structure can be gained via a small area of mucosa just posterior and superior to the tail of the middle turbinate on the lateral nasal wall. At this aspect, there is no bony boundary to the SPG. Blocking the SPG using local anesthetics relieves pain. Unfortunately, many current interventions are cumbersome, invasive, and expensive. The purpose of this study is to evaluate the efficacy of the Tx360™, a new nasal applicator device, in the treatment of head and face pain and to examine the economic implications. The Tx360™ is a single use device designed to deliver a topical local anesthetic to the specific area of mucosa associated with the SPG. A total of 42 study participants will be accepted into this double-blind placebo-controlled study. 28 will receive SPG blocks using a 0.3 mL of a 0.5% solution of Marcaine delivered by the Tx360™ while 14 will receive a placebo of saline substituted for the Marcaine. Both patient sets will also be given a piece of lemon hard candy as a taste distractor. Participants must have a chronic migraine history with over 15 symptomatic days per month over the past three months. The treatment plan consists of six weeks of treatment, two times per week. Short and longer term assessments will be retrieved and analyzed as detailed in the Study Design.
42 study participants will be included in this double-blind placebo-controlled study. Following enrollment of 42 subjects and completion of the 6-week Treatment Period by all active subjects, an analysis of the treatment effect will be performed for a reassessment of sample size and, if deemed appropriate, the study will continue with enrollment of additional subjects to ensure a more statistically robust interpretation of the data. The results of the statistical analysis will be blinded from Investigators and coordinators. The procedure will be delivered to all subjects who agree to participate, meet inclusion criteria, and sign informed consent.
At Visit 1 following Informed Consent, a physical exam and vital signs will be completed. A medical, headache, and medication history (to include age, sex, height and weight, and duration and location of headache pain, as well as history of ER visits) will be collected on all subjects. Eligible subjects will be provided with a Baseline Headache Diary and instructed to treat migraines for the following month in their usual manner with their usual treatment. The daily Diary will document headache, acute treatment and response, and migraine associated symptoms (nausea, vomiting, light sensitivity, or sound sensitivity) to establish a Baseline number of headache days and severity. Visit 2 will be scheduled for 1 month following Visit 1. Following Visit 1, Visits 2-13 (treatment visits) will be scheduled to occur twice weekly (during the regular Monday - Friday work week) at least 2 days apart. Treatments should not occur on consecutive days.
At Visit 2, the Baseline Headache Diary will be reviewed and those subjects continuing to meet eligibility will be dispensed a 6-week Treatment Period Diary and complete Before Procedure questions to include the Pain Intensity Numeric Rating Scale (NRS), the Modified Pain Characteristic Questionnaire, and a baseline Headache Impact Test-6 (HIT-6), have vital signs completed, and the medical, headache, and medication history updated. Subjects will be randomized 2:1 to Group A or Group B. Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the SPG. Group B will receive saline substituted for Marcaine delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.
To maintain the blinding of the treatment groups, neither the Investigator nor research personnel who are involved in evaluating the subject should prepare the study medication. An independent research staff person with no involvement in the study conduct will place study medication (either Marcaine for a subject randomized to Group A or Placebo/saline for a subject randomized to Group B) in a 1cc Luer Lok tip syringe and assemble the syringe and Tx360TM catheter as instructed in training. A label with the subject Drug Number will be placed on the device at that time. The research staff person administering the study medication will verify that the Drug Number assignment is correct.
Both Groups will be given a piece of lemon hard candy as a taste distractor.
At each treatment visit (Visits 2-13), in addition to Before Procedure questions, subjects will complete 15-minute and 30-minute After Procedure questionnaires to include the NRS and, at 30 minutes, the Patient's Global Impression of Change (PGIC). Subjects will take home a questionnaire to include the NRS, PGIC, satisfaction question, and the Modified Pain Characteristic Questionnaire to be completed at 24 hours following treatment and be instructed to return the 24-hour After Procedure questionnaire to the clinic at the next visit.
At Visits 2-15 vital signs will be completed, medications will be updated, and Non-Serious Adverse Events will be collected after the first treatment. Serious Adverse Events will be collected once the informed consent has been signed and throughout the study.
At Visits 5, 8, and 11, the Treatment Period Headache Diary will be collected, reviewed, and re-dispensed.
At Visit 13, the 1-Month Post-Treatment Period Diary will be dispensed.
The subject will return to the clinic at Visit 14 between 24 and 96 hours following the final treatment at Visit 13 to return the 24-hour After Procedure Questionnaire and complete the 1-Month Treatment Period HIT-6. The Treatment Period Diary will be collected.
At Visit 15, 1 month following the final treatment, each subject will return to the clinic and complete a 1-Month Follow Up HIT-6 and the 1-Month Follow Up Questionnaire. The 1-Month Post-Treatment Period Diary will be collected.
At 6 months following the final treatment, each subject will be phoned to complete the 6-Month Follow Up Questionnaire to include the NRS, PGIC, satisfaction question, the Modified Pain Characteristic Questionnaire, and a 6-Month Follow Up HIT-6.
Treatment Medication Subjects randomized to Group A will be administered 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the SPG. Twelve treatments will be administered over a period of 6 weeks.
Subjects randomized to Group B will be administered saline substituted for Marcaine delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG for treatment of chronic migraine. Twelve treatments will be administered over a period of 6 weeks.
Rescue Medication Subjects will be allowed to rescue with medication mutually agreed upon by subject and Investigator at the time of screening.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female of , agrees to use, for the duration of the study, a medically acceptable form of as determined by the Investigator.
Exclusion Criteria:
If female of , agrees to use, for the duration of the study, a medically acceptable form of as determined by the Investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the Sphenopalatine Ganglion (SPG)
Drug: Marcaine
Group B will receive saline placebo delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.
Drug: Saline
Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
Also known as: Bupivicane (generic)
Saline
Numeric Rating Scale (NRS)
Compare Numeric Rating Scale (NRS) scores Before Procedure,15-Minute Post Treatment, 30-Minutes Post Treatment, 24-Hour Post Treatment for all 12 treatments (Marcaine vs. Saline). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain. For each individual time point, all 12 treatments were averaged for that time point and a single value was used for comparison between the two groups.
Time frame: 6 Weeks
Change in Numeric Rating Scale (NRS)
Compare percentage change in Numeric Rating Scale (NRS) score from Before Procedure to 15-Minutes, Before Procedure to 30-Minutes, Before Procedure to 24-Hours After Procedure for all 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain.
Time frame: 15 Minutes Post Treatment, 30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks
Patient's Global Impression of Change (PGIC)
Compare 24-Hour After Procedure Patient's Global Impression of Change (PGIC) score for 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). PGIC is a likert scale ranging from 1 to 7 with 1 being very much improved and 7 being very much worse.
Time frame: 30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks
Modified Pain Characteristic Questionnaire
Compare Modified Pain Characteristic Questionnaire scores Before Procedure vs. 24-Hour After Procedure, Before Procedure vs. 1-Month Follow Up, and Before Procedure vs. 6-Month Follow Up (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). The modified pain characteristic questionnaire is a series of 11 questions on a likert scale ranging from 0 to 10 with 0 being no pain or does not interfere and 10 being worst pain or completely interferes. Percentage questions range from 0 to 100.
Time frame: Before Treatment, 24 Hours After Treatment, 1 Month Post Treatment, and 6 Months Post Treatment
Migraine Headache Days
Compare change in the number of migraine headache days per month reported in Baseline Period Diary vs. Treatment Period Diary vs. Post-Treatment Period Diary.
Time frame: 12 Weeks
Acute Medications Usage
Number of acute medications used during Treatment period (6 weeks) and Follow-Up (4 weeks) (Group A vs. Group B).
Time frame: 10 Weeks
Adverse Events
Number of adverse events over the entire length of study (Group A vs. Group B).
Time frame: 34 weeks
Headache Impact Test (HIT-6)
Total Headache Impact Test (HIT-6) scores Pre-Treatment at Visit 2 vs. Post-Treatment (following final treatment), and at 1-Month Post-Treatment (Group A vs. Group B). HIT-6 is a series of 6 likert scale questions ranging from 1 to 5 with 1 being never and 5 being always. The HIT-6 answer options are weighted as follows: Never (1) = 6 points each, Rarely (2) = 9 points each, Sometimes (3) = 10 points each, Very often (4) = 11 points each, Always (5) = 13 points each. The total score for the HIT-6 ranges from 36 (subject answers all 6 questions as "Never") to 78 subject answers all 6 questions as "Always"), with higher total scores indicating more impact than lower scores, i.e., headaches cause greater impact on the subject's life.
Time frame: 10 Weeks
Overall Satisfaction
Satisfaction scores Visit 2 vs. following treatment (Treatment 12) and at 1-Month Post-Treatment (Group A vs. Group B). Satisfaction scores are a likert scale ranging from 1 to 5 with 1 being complete dissatisfaction and 5 being complete satisfaction.
Time frame: 10 Weeks
| Milestone | Marcaine | Saline |
|---|---|---|
| Started | 27 | 14 |
| Completed | 26 | 12 |
| Not completed | 1 | 2 |
| Withdrew: Protocol violation | 1 | 2 |
Compare Numeric Rating Scale (NRS) scores Before Procedure,15-Minute Post Treatment, 30-Minutes Post Treatment, 24-Hour Post Treatment for all 12 treatments (Marcaine vs. Saline). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain. For each individual time point, all 12 treatments were averaged for that time point and a single value was used for comparison between the two groups.
| units on a scale | Marcaine | Saline |
|---|---|---|
| Before Procedure | 3.18 ± 2.79 | 3.78 ± 2.48 |
| 15 Minutes Post Treatment | 2.53 ± 2.61 | 3.51 ± 2.39 |
| 30 Minutes Post Treatment | 2.41 ± 2.61 | 3.45 ± 2.36 |
| 24 Hours Post Treatment | 2.85 ± 2.74 | 4.20 ± 2.62 |
Compare percentage change in Numeric Rating Scale (NRS) score from Before Procedure to 15-Minutes, Before Procedure to 30-Minutes, Before Procedure to 24-Hours After Procedure for all 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain.
| percentage of change | Marcaine | Saline |
|---|---|---|
| 15 Minutes Post Treatment | -23.3 ± 34.5 | -4.31 ± 27.3 |
| 30 Minutes Post Treatment | -27.7 ± 37.1 | -5.41 ± 29.2 |
| 24 Hours Post Treatment | -15.5 ± 69.9 | 13.5 ± 78.8 |
Compare 24-Hour After Procedure Patient's Global Impression of Change (PGIC) score for 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). PGIC is a likert scale ranging from 1 to 7 with 1 being very much improved and 7 being very much worse.
| units on a scale | Marcaine | Saline |
|---|---|---|
| 30 Minutes Post Treatment | 3.00 ± 1.02 | 3.72 ± 0.53 |
| 24 Hours Post Treatment | 3.08 ± 1.26 | 3.88 ± 1.02 |
Compare Modified Pain Characteristic Questionnaire scores Before Procedure vs. 24-Hour After Procedure, Before Procedure vs. 1-Month Follow Up, and Before Procedure vs. 6-Month Follow Up (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). The modified pain characteristic questionnaire is a series of 11 questions on a likert scale ranging from 0 to 10 with 0 being no pain or does not interfere and 10 being worst pain or completely interferes. Percentage questions range from 0 to 100.
| units on a scale | Marcaine | Saline |
|---|---|---|
| Worst Pain Question: Before Treatment | 4.75 ± 3.11 | 6.15 ± 2.65 |
| Worst Pain Question: 24 Hours After Treatment | 4.36 ± 3.01 | 6.16 ± 2.44 |
| Worst Pain Question: 1 Month Post Treatment | 4.56 ± 3.23 | 5.64 ± 3.04 |
| Worst Pain Question: 6 Months Post Treatment | 4.27 ± 3.10 | 5.88 ± 1.73 |
| Least Pain Question: Before Treatment | 2.01 ± 2.55 | 2.50 ± 2.13 |
| Least Pain Question: 24 Hours After Treatment | 1.77 ± 2.49 | 2.43 ± 1.93 |
| Least Pain Question: 1 Month Post Treatment | 1.88 ± 2.62 | 2.64 ± 2.11 |
| Least Pain Question: 6 Months Post Treatment | 1.68 ± 2.03 | 2.88 ± 2.47 |
| Average Pain Question: Before Treatment | 3.39 ± 2.61 | 4.33 ± 2.29 |
| Average Pain Question: 24 Hours After Treatment | 3.07 ± 2.57 | 4.27 ± 2.09 |
| Average Pain Question: 1 Month Post Treatment | 3.36 ± 2.87 | 3.91 ± 2.30 |
| Average Pain Question: 6 Months Post Treatment | 2.86 ± 2.62 | 4.00 ± 2.27 |
| Percent Relief Question: Before Treatment | 41.3 ± 36.5 | 29.2 ± 33.0 |
| Percent Relief Question: 24 Hours After Treatment | 46.0 ± 38.2 | 29.8 ± 32.5 |
| Percent Relief Question: 1 Month Post Treatment | 46.3 ± 39.9 | 21.0 ± 32.1 |
| Percent Relief Question: 6 Months Post Treatment | 34.7 ± 29.2 | 18.6 ± 30.8 |
| General Activity Question: Before Treatment | 2.49 ± 2.96 | 3.50 ± 2.70 |
| General Activity Question: 24 Hours After Treatmen | 2.31 ± 2.90 | 3.64 ± 2.78 |
| General Activity Question: 1 Month Post Treatment | 2.64 ± 2.91 | 3.91 ± 2.81 |
| General Activity Question: 6 Months Post Treatment | 2.68 ± 2.87 | 4.00 ± 3.32 |
| Mood Interference Question: Before Treatment | 2.57 ± 3.07 | 3.78 ± 2.84 |
| Mood Interference Question: 24 Hours After Treatme | 2.42 ± 3.06 | 4.19 ± 3.04 |
| Mood Interference Question: 1 Month Post Treatment | 2.96 ± 3.43 | 3.82 ± 3.40 |
| Mood Interference Question: 6 Months Post Treatmen | 3.18 ± 3.26 | 5.71 ± 3.68 |
| Walking Ability Question: Before Treatment | 0.63 ± 1.27 | 1.27 ± 2.24 |
| Walking Ability Question: 24 Hours After Treatment | 0.54 ± 1.33 | 1.24 ± 2.37 |
| Walking Ability Question: 1 Month Post Treatment | 0.80 ± 1.68 | 0.55 ± 0.93 |
| Walking Ability Question: 6 Months Post Treatment | 0.45 ± 1.74 | 0.43 ± 1.13 |
| Normal Work Question: Before Treatment | 2.53 ± 3.08 | 3.49 ± 2.81 |
| Normal Work Question: 24 Hours After Treatment | 2.21 ± 3.02 | 3.63 ± 2.97 |
| Normal Work Question: 1 Month Post Treatment | 2.52 ± 3.14 | 3.45 ± 2.94 |
| Normal Work Question: 6 Months Post Treatment | 2.59 ± 2.77 | 3.71 ± 3.50 |
| Relationships Question: Before Treatment | 2.00 ± 2.87 | 3.47 ± 2.92 |
| Relationships Question: 24 Hours After Treatment | 1.96 ± 2.87 | 3.90 ± 3.09 |
| Relationships Question: 1 Month Post Treatment | 2.36 ± 3.29 | 3.09 ± 3.45 |
| Relationships Question: 6 Months Post Treatment | 2.05 ± 2.87 | 3.86 ± 3.98 |
| Sleep Interference Question: Before Treatment | 2.29 ± 3.09 | 2.68 ± 3.11 |
| Sleep Interfere Question: 24 Hours After Treatment | 1.89 ± 3.03 | 2.85 ± 3.22 |
| Sleep Interferenc Question: 1 Month Post Treatment | 1.92 ± 3.00 | 2.55 ± 3.47 |
| Sleep Interference Question: 6 Months Post Treatme | 1.55 ± 2.32 | 3.14 ± 3.93 |
| Enjoyment Question: Before Treatment | 2.81 ± 3.24 | 3.12 ± 2.74 |
| Enjoyment Question: 24 Hours After Treatment | 2.58 ± 3.29 | 3.34 ± 2.89 |
| Enjoyment Question: 1 Month Post Treatment | 2.64 ± 3.51 | 3.09 ± 2.91 |
| Enjoyment Question: 6 Months Post Treatment | 3.18 ± 3.36 | 4.00 ± 4.12 |
Compare change in the number of migraine headache days per month reported in Baseline Period Diary vs. Treatment Period Diary vs. Post-Treatment Period Diary.
| Migraine headache days per month | Marcaine | Saline |
|---|---|---|
| Baseline | 15.0 ± 6.33 | 15.8 ± 7.40 |
| Treatment | 12.3 ± 8.83 | 12.2 ± 9.69 |
| Post Treatment | 10.8 ± 9.22 | 11.3 ± 8.32 |
Number of acute medications used during Treatment period (6 weeks) and Follow-Up (4 weeks) (Group A vs. Group B).
| Number of medications used | Marcaine | Saline |
|---|---|---|
| Acute Medications Usage | 29.3 ± 28.2 | 47.4 ± 54.2 |
Number of adverse events over the entire length of study (Group A vs. Group B).
| Number of Adverse Events | Marcaine | Saline |
|---|---|---|
| Adverse Events | 7.67 ± 8.23 | 5.29 ± 7.02 |
Total Headache Impact Test (HIT-6) scores Pre-Treatment at Visit 2 vs. Post-Treatment (following final treatment), and at 1-Month Post-Treatment (Group A vs. Group B). HIT-6 is a series of 6 likert scale questions ranging from 1 to 5 with 1 being never and 5 being always. The HIT-6 answer options are weighted as follows: Never (1) = 6 points each, Rarely (2) = 9 points each, Sometimes (3) = 10 points each, Very often (4) = 11 points each, Always (5) = 13 points each. The total score for the HIT-6 ranges from 36 (subject answers all 6 questions as "Never") to 78 subject answers all 6 questions as "Always"), with higher total scores indicating more impact than lower scores, i.e., headaches cause greater impact on the subject's life.
| units on a scale | Marcaine | Saline |
|---|---|---|
| Pre-Treatment | 64.36 ± 4.93 | 64 ± 3.92 |
| Post-Treatment | 59.85 ± 8.33 | 62.5 ± 4.96 |
| 1-Month Post-Treatment | 59.23 ± 8.97 | 61.92 ± 5.45 |
Satisfaction scores Visit 2 vs. following treatment (Treatment 12) and at 1-Month Post-Treatment (Group A vs. Group B). Satisfaction scores are a likert scale ranging from 1 to 5 with 1 being complete dissatisfaction and 5 being complete satisfaction.
| units on a scale | Marcaine | Saline |
|---|---|---|
| Visit 2 | 3.52 ± 0.75 | 3.00 ± 0.89 |
| Following treatment (Treatment 12) | 3.55 ± 1.00 | 2.50 ± 0.97 |
| 1-Month Post-Treatment | 3.57 ± 0.99 | 2.64 ± 1.12 |
Collected over Adverse events were collected from the time of signing the informed consent until study exit. The length of study participation was 34 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Marcaine | — | 0/27 (0%) | 9/27 (33.3%) |
| Saline | — | 1/14 (7.1%) | 5/14 (35.7%) |
| Event | Marcaine | Saline |
|---|---|---|
| Pulmonary Embolism Resulting in DeathCardiac disorders | 0/27 | 1/14 |
| Event | Marcaine | Saline |
|---|---|---|
| ColdRespiratory, thoracic and mediastinal disorders | 9/27 | 2/14 |
| LacrimationEye disorders | 8/27 | 1/14 |
| Bad TasteGeneral disorders | 7/27 | 1/14 |
| Mouth NumbnessGeneral disorders | 6/27 | 0/14 |
| Nasal IrritationGeneral disorders | 4/27 | 3/14 |
| DizzinessGeneral disorders | 0/27 | 2/14 |
| Ear RingingEar and labyrinth disorders | 0/27 | 2/14 |
| Light HeadednessGeneral disorders | 1/27 | 2/14 |
| Sore ThroatGeneral disorders | 2/27 | 2/14 |
| Age, Continuous(years) | Marcaine | Saline | Total |
|---|---|---|---|
| Mean | 40.96 ± 11.63 | 41.97 ± 14.71 | 41.30 ± 12.59 |
| Sex: Female, Male(Participants) | Marcaine | Saline | Total |
|---|---|---|---|
| Female | 20 | 11 | 31 |
| Male | 7 | 3 | 10 |
| Race (NIH/OMB)(Participants) | Marcaine | Saline | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 0 | 4 |
| White | 20 | 14 | 34 |
| More than one race | 3 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
The record gives a start of Sep 2012, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupivacaine
Tian Medical Inc.